Tag Archives: Warren Woessner

Federal Circuit Grants Ariad’s Petition for Rehearing En Banc to Settle WDR Hash.

Posted on August 24, 2009 by Warren Woessner

At long last, the Federal Circuit will specifically address the questions of (a) whether or not section 112 contains a written description requirement separate from the enablement requirement and, if it does (b) what is its scope and purpose. Hopefully, … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , | 1 Comment

Warren Woessner Participates In Virtual Debate With Chris Hansen On The Myriad Lawsuit

Posted on August 17, 2009 by Warren Woessner

Cameron MacKendrick sponsors podcasts on issues of interest in IP law. In this one, I am trying to explain the debate surrounding both the patentability of “natural products” as well as the patentability of diagnostic assays and their relationship t … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | Leave a comment

UNIVERSITY OF PITTSBURGH v. HEDRICK – ON A (CLEAR) CONCEPTION DAY

Posted on July 27, 2009 by Warren Woessner

From a prosecutor’s standpoint, the ‘231 patent (link at bottom of this post) has “dream claims” to a new class of stem cells. Claim 1 reads: An isolated adipose-derived stem cell that can differentiate into two or more of the … Continue reading →

Posted in Organization/Business News, Tech Transfer | Tagged , , , , , , , , | Leave a comment

BIOTECH INDUSTRY IN MINNESOTA – STAYIN’ ALIVE

Posted on July 27, 2009 by Warren Woessner

In its July 3rd issue, the Minneapolis St. Paul Business Journal published a list of the “Top 25 Biotech Companies.” It tells a pretty sad story. The top 25 companies together employ fewer than 3000 workers in Minnesota. The top … Continue reading →

Posted in Organization/Business News | Tagged , , | Leave a comment